E-Mail
A study led by researchers at Baylor College of Medicine reveals a novel role of the steroid receptor coactivator 3 (SRC-3/NCOA3), a protein crucial for steroid hormone function and a prognostic marker for aggressive human breast and other cancers.
The team discovered that SRC-3 also regulates human immune T regulatory cells (Tregs), which contribute to the regulation of the body s immunological activity by suppressing the function of other immune cells, including those involved in fighting cancer. The study, which appears in the journal
Scientific Reports, shows that Tregs whose SRC-3 function was eliminated failed to suppress the activity of other immune cells in the lab. The authors anticipate that their findings may help in the fight against cancer in the future by leading to new approaches to inhibit Tregs activity which consequently would release immune attack in tumors.
E-Mail
A study led by researchers at Baylor College of Medicine reveals a novel role of the steroid receptor coactivator 3 (SRC-3/NCOA3), a protein crucial for steroid hormone function and a prognostic marker for aggressive human breast and other cancers.
The team discovered that SRC-3 also regulates human immune T regulatory cells (Tregs), which contribute to the regulation of the body s immunological activity by suppressing the function of other immune cells, including those involved in fighting cancer. The study, which appears in the journal
Scientific Reports, shows that Tregs whose SRC-3 function was eliminated failed to suppress the activity of other immune cells in the lab. The authors anticipate that their findings may help in the fight against cancer in the future by leading to new approaches to inhibit Tregs activity which consequently would release immune attack in tumors.
Heart failure after a significant heart attack is a leading cause of death in humans. It often occurs over a few years; a person becomes weaker and weaker and eventually dies. There are very few preventative therapies.
At Baylor College of Medicine, a team of researchers has found a potential treatment that has shown promising results in mice.
Dr. Bert O’Malley
“In the mouse model, our team has been able to show that a molecule known as MCB-613 decreases damaging remodeling when given within hours after a myocardial infarction, thereby inhibiting the subsequent development of heart failure,” said Dr. Bert O’Malley, professor of molecular and cellular biology at Baylor and lead author of the study.